Central nervous system manifestations of rheumatologic diseases

Current Opinion in Rheumatology

Volumn 17, Issue 1, 2005, Pages 91-99

  Chin, Russell L ^a   Latov, Norman ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Beh et disease; Central nervous system; Connective tissue disease; Neurologic complications; Primary angiitis of the central nervous system; Rheumatoid arthritis; Sj gren syndrome; Systemic lupus erythematosus; Systemic sclerosis; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; PREDNISONE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; WARFARIN;

AORTA ANEURYSM; AORTA ARCH SYNDROME; ARTERY DISSECTION; ARTERY OCCLUSION; BEHCET DISEASE; BRAIN VASCULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CRANIAL NEUROPATHY; GIANT CELL ARTERITIS; HUMAN; HYPERLIPIDEMIA; INTRACRANIAL HYPERTENSION; ISCHEMIA; KIDNEY DISEASE; LUNG DISEASE; MENTAL DISEASE; MOTOR DYSFUNCTION; MYELITIS; NECK PAIN; NECROTIZING ARTERITIS; NEUROGENIC BLADDER; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SEIZURE; SENSORY NEUROPATHY; SJOEGREN SYNDROME; SPINAL CORD DISEASE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK; VASCULAR HEADACHE; VISUAL DISORDER; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; RHEUMATIC DISEASES; VASCULITIS;

EID: 11344259267     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000149085.54756.a4     Document Type: Review

References (109)

1. Rosenbaum R: Neuromuscular complications of connective tissue diseases. Muscle Nerve 2001, 24:154-169.
2. Younger D: Vasculitis and the nervous system. Curr Opin Neurol 2004, 17:317-336.
3. Moore PM, Cupps TR: Neurological complications of vasculitis. Ann Neurol 1983, 14:155-167.
4. Guillevin L, Lhote F, Gherardi R: Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome: clinical aspects, neurologic manifestations and treatment. Neurol Clin 1997, 15:865-886.
5. Paula De Carvalho Panzeri Carlotti A, Paes Leme Ferriani V, Tanuri Caldas C, et al.: Polyarteritis nodosa with central nervous system involvement mimicking meningoencephalitis. Pediatr Crit Care Med 2004, 5:286-288.
6. Nishino H, Rubino FA, DeRemee RA, et al.: Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993, 33:4-9.
7. Rosenblatt BJ, Foroozan R, Savino PJ: Asymptomatic optic neuropathy associated with Churg-Strauss syndrome. Ophthalmology 2003, 110:1650-1652.
8. Carr J, Bryer A: An isolated myelopathy as a presentation of polyarteritis nodosa. Br J Rheumatol 1993, 32:644.
9. Shannon KM, Goetz CG: Connective tissue diseases and the nervous system. In: Neurology and General Medicine. Edn 3, Edited by Aminoff MJ. Philadelphia: Churchill Livingstone; 2001:459-481.
10. Reichhart MD, Bogousslavsky J, Janzer RC: Early lacunar strokes complicating polyarteritis nodosa: thrombotic microangiopathy. Neurology 2000, 54:883-889.
11. Calabrese LH, Furlan AJ, Gragg LA, et al.: Primary angiitis of the central nervous system: diagnostic criteria and clinical approach. Cleve Clin J Med 1992, 59:293-306.
12. Ohkoshi N, Mizusawa H, Oguni E, et al.: Sural nerve biopsy in vasculitic neuropathies: morphometric analysis of the caliber of involved vessels. J Med 1996, 27:153.
13. Gurer G, Erdem S, Kocaefe C, et al.: Expression of matrix metalloproteinases in vasculitic neuropathy. Rheumatol Int 2003, Nov 4 [Epub ahead of print] The matrix metalloproteinase MMP-9, an endopeptidase that degrades components of the extracellular matrix, may play a pathogenic role in the development of vasculitic neuropathy.
14. Heuss D, Probst-Cousin S, Kayser C, et al.: Cell death in vasculitic neuropathy. Muscle Nerve 2000, 23:999-1004.
15. Hu W, Mathey E, Hartung HP, et al.: Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve. Neurology 2003, 61:1774-1779. Cyclooxygenase-2 mRNA was found to be upregulated in patients with vasculitic neuropathy.
16. Lindenlaub T, Sommer C: Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol (Berl) 2003, 105:593-602. Increased cytokine expression in vasculitic neuropathy was found to positively correlate with neuropathic pain.
17. Yamamoto M, Ito Y, Mitsuma N, et al.: Pain-related differential expression of NGF, GDNF, IL-6, and their receptors in human vasculitic neuropathies. Intern Med 2003, 42:1100-1103.
18. Haslbeck K-M, Bierhaus A, Schliecher E, et al.: Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-κB activation in vasculitic neuropathy. Muscle Nerve 2004, 29:853-860. The receptor for advanced glycation endproduct pathway may play a critical proinflammatory role in vasculitic neuropathy. The possible therapeutic targets are discussed.
19. Hoffman GS, Kerr GS, Leavitt RY, et al.: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
20. Nagashima T, Maguchi S, Terayama Y, et al.: P-ANCA-positive Wegener's granulomatosis presenting with hypertrophic pachymeningitis and multiple cranial neuropathies: case report and review of literature. Neuropathology 2000, 20:23-30.
21. Fam AG, Lavine E, Lee L, et al.: Cranial pachymeningitis: an unusual manifestation of Wegener's granulomatosis. J Rheumatol 2003, 30:2070-2074.
22. Haynes BF, Fishman ML, Fauci AS, et al.: The ocular manifestations of Wegener's granulomatosis: fifteen years experience and review of the literature. Am J Med 1977, 63:131-141.
23. Fauci AS, Haynes BF, Katz P, et al.: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983, 98:76-85.
24. Provenzale JM, Allen NB: Neuroradiologic findings in polyarteritis nodosa. AJNR Am J Neuroradiol 1996, 17:1119-1126.
25. Murphy JM, Gomez-Anson B, Gillard JH, et al.: Wegener granulomatosis: MR imaging findings in brain and meninges. Radiology 1999, 213:794-799.
26. Spranger M, Schwab S, Meinck H-M, et al.: Meningeal involvement in Wegener's granulomatosis confirmed and monitored by positive circulating antineutrophil cytoplasm in cerebrospinal fluid. Neurology 1997, 48:263-265.
27. Weyand CM, Goronzy JJ: Mechanisms of disease: medium- and large-vessel vasculitis. N Engl J Med 2003, 349:160-169.
28. Nesher G, Berkun Y, Mates M, et al.: Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 2004, 83:114-122. This retrospective review of 175 patients with GCA found that transient cerebroophthalmic ischemic episodes and male sex were risk factors for ischemic complications, whereas the presence of systemic symptoms was "protective."
29. Seo P, Stone JH: Large-vessel vasculitis. Arthritis Rheum 2004, 51:128-139. This excellent two-part report on vasculitis focuses on common questions that confront physicians regarding the diagnosis and treatment of these conditions.
30. Cid MC, Font C, Oristrell J, et al.: Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998, 41:26-32.
31. Achkar AA, Lie JT, Hunder GG, et al.: How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994, 120:987-992.
32. Ray-Chaudhuri N, Kine DA, Tijani SO, et al.: Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol 2002, 86:530-532.
33. Varma D, O'Neill D: Quantification of the role of temporal artery biopsy in diagnosing clinically suspected giant cell arteritis. Eye 2004, 18:384-388.
34. Younge BR, Cook BE Jr, Bartley GB, et al.: Initiation of glucocorticoid therapy: before or after temporal artery biopsy? Mayo Clin Proc 2004, 79:483-491. Of 1113 patients who underwent temporal artery biopsy in a 10-year period, 34% were found to have GCA. The presence of jaw claudication, new headache, scalp tenderness, and decreased vision had positive predictive values.
35. Hamidou MA, Moreau A, Toquet C, et al.: Temporal arteritis associated with systemic necrotizing vasculitis. J Rheumatol 2003, 30:2165-2169.
36. Reinhard M, Schmidt D, Schumacher M, et al.: Involvement of the vertebral arteries in giant cell arteritis mimicking vertebral dissection. J Neurol 2003, 250:1006-1009.
37. Nuenninghoff DM, Hunder GG, Christianson TJ, et al.: Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003, 48:3522-3531. In this retrospective review, 27% of 168 patients with GCA experienced large artery complications. Hyperlipidemia and coronary artery disease were associated risk factors. Cranial symptoms and a higher erythrocyte sedimentation rate were negatively associated with large artery stenosis.
38. Caselli RJ, Hunder GG, Whisnant JP: Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988, 38:352-359.
39. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al.: Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998, 41:1497-1504.
40. Shroff GR, Karnad DR, Limaye US, et al.: Isolated cranial nerve syndromes without proximal carotid involvement in aortoarteritis. Ann Rheum Dis 2004, 63:465-466.
41. Lee S-Y, Chu K, Park K-I, et al.: Diffusion-weighted MR findings in isolated angiitis of the central nervous system (IACNS). Acta Neurol Scand 2003, 108:346-351. The heterogenous MR findings in two patients likely reflect the various stages of the disease.
42. Calabrese LH, Duna GF, Lie JT: Vasculitis in the central nervous system. Arthritis Rheum 1997, 40:1189-1201.
43. Calabrese LH, Mallek JA: Primary angiitis of the central nervous system: report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore) 1988, 67:20-39.
44. Alreshaid AA, Powers WJ: Prognosis of patients with suspected primary CNS angiitis and negative brain biopsy. Neurology 2003, 61:831-833. This case series of 25 patients found a lack of treatment effect in patients with suspected primary CNS and nondiagnostic brain biopsy results who received immunosuppressive drugs.
45. Gold R, Fontana A, Zierz S: Therapy of neurological disorders in systemic vasculitis. Semin Neurol 2003, 23:207-214.
46. Akman-Demir G, Serdaroǧlu P, Taşçi B, and the Neuro-Behçet Study Group: Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain 1999, 122:2171-2182.
47. Al-Araji A, Sharquie K, Al-Rawi Z: Prevalence and patterns of neurological involvement in Behcet's disease: a prospective study from Iraq. J Neurol Neurosurg Psychiatry 2003, 74:608-613.
48. Monastero R, Camarda C, Pipia C: Cognitive impairment in Behcet's disease patients without overt neurological involvement. J Neurol Sci 2004, 220:99-104. Impaired memory (long-term verbal and nonverbal) and visuospatial skills were found to occur frequently in patients with active disease who were taking large doses of steroids.
49. Siva A, Altintas A, Saip S: Behcet's syndrome and the nervous system. Curr Opin Neurol 2004, 17:347-357. This excellent review highlights the current understanding of the clinical spectrum of the disease.
50. Evans RW, Akman-Demir G: Behçet syndrome and headache. Headache 2004, 44:102-104.
51. Palacio E, Rodero L, Pascual J: Topiramate-responsive headache due to idiopathic intracranial hypertension in Behcet syndrome. Headache 2004, 44:436-437.
52. Akman-Demir G, Bahar S, Coban O, et al.: Cranial MRI in Behcet's disease: 134 examinations of 98 patients. Neuroradiology 2003, 45:851-859. This article reviews the MRI findings in patients with differing disease courses, that is, active, primary progressive, or secondarily progressive disease.
53. Kunimatsu A, Abe O, Aoki S, et al.: Neuro-Behcet's disease: analysis of apparent diffusion coefficients. Neuroradiology 2003, 45:524-527.
54. Saruhan-Direskeneli G, Yentür SP, Akman-Demir G, et al.: Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 2003, 145:127-134. In this detailed study, the serum and CSF levels of various cytokines and chemokines were evaluated in patients with Behçet disease, multiple sclerosis, inflammatory neurologic disease, and noninflammatory neurologic diseases. The profile in patients with Behçet disease resembled nonspecific inflammation more than autoimmune disorders such as multiple sclerosis.
55. ACR ad hoc committee on neuropsychiatric lupus nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42:599-608.
56. Jennekens FGI, Kater L: The central nervous system in systemic lupus erythematosus: Part 1. Clinical syndromes: a literature investigation. Rheumatol 2002, 41:605-618.
57. Mitsikostas DD, Sfikakis PP, Goadsby PJ: A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 2004, 127:1200-1209. This excellent review found that the incidence of all headache types, including migraine, in patients with SLE did not significantly differ from the incidence in control individuals. Insufficient evidence was found for the concept of "lupus headache."
58. Kwon SU, Koh JY, Kim JS: Vertebrobasilar artery territory infarction as an initial manifestation of systemic lupus erythematosus. Clin Neurol Neurosurg 1999, 101:62-67.
59. Olfat MO, Al-Mayouf SM, Muzaffer MA: Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol 2004, 23: (Epub).
60. Csepany T, Bereczki D, Kollar J, et al.: MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. J Neurol 2003, 250:1348-1354.
61. Sibbitt WL Jr, Schmidt PJ, Hart BL, et al.: Fluid attenuated inversion recovery (FLAIR) imaging in neuropsychiatric systemic lupus erythematosus. J Rheumatol 2003, 30:1983-1989.
62. Williams RC Jr, Sugiura K, Tan EM: Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2004, 50:1239-1247. Autoantibodies to microtubule-associated protein-2, a neuron-restricted cytoskeletal protein, were found in 17% of SLE patients versus 4% in the control group. Anti-microtubule-associated protein-2 positivity, like anti-ribosomal P antibody positivity, was associated with severe neuropsychiatric symptoms.
63. Alfetra A, Garzia P, Mitterhofer AP, et al.: Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 2003, 61:108-110.
64. Sanna G, Bertolaccini ML, Cuadrado MJ, et al.: Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003, 30:985-992.
65. Katzav A, Chapman J, Shoenfeld Y: CNS dysfunction in the antiphospholipid syndrome. Lupus 2003, 12:903-907.
66. De Groot PG, Derksen RH: Antiphospholipid antibodies: update on detection, pathophysiology, and treatment. Curr Opin Hematol 2004, 11:165-169.
67. Levine SR, Brey RL, Tilley BC, et al.: Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004, 29:576-584.
68. van Goor MP, Alblas CL, Leebeek FW, et al.: Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? Acta Neurol Scand 2004, 109:410-415. In this paper, 17% of 128 patients aged 18 to 45 years with recent transient ischemic attack or ischemic stroke had aPL, which did not seem to be a strong risk factor for recurrent stroke or transient ischemic attack.
69. Chaves CJ: Stroke in patients with systemic lupus erythematosus and antiphospholipid antibody syndrome. Curr Treat Options Cardiovasc Med 2004, 6:223-229. In this review, high-level oral anticoagulation is the preferred treatment for patients who have experienced strokes, particularly those with left-sided cardiac valve lesions and persistent high titers of immunoglobulin G antiphospholipid antibodies.
70. Sanna G, Bertolaccini ML, Mathieu A: Central nervous system lupus: a clinical approach to therapy. Lupus 2003, 12:935-942.
71. Dong Y, Zhang X, Tang F, et al.: Intrathecal injection with methotrexate plus dexamethasone in the treatment of central nervous system involvement in systemic lupus erythematosus. Chin Med J (Engl) 2001, 114:764-766.
72. Baca V, Lavalle C, Garcia R, et al.: Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999, 26:432-439.
73. Tumialan LM, Wippold FJ II, Morgan RA: Tortuous vertebral artery injury complicating anterior cervical spinal fusion in a symptomatic rheumatoid cervical spine. Spine 2004, 29:E323-E348.
74. Naranjo A, Carmona L, Gavrila D, et al.: Prevalence and associated factors of anterior atlantoaxial subluxation in a nation-wide sample of rheumatoid arthritis patients. Clin Exp Rheumatol 2004, 22:427-432.
75. Levy Y, Stalley P, Bleasel J: Thoracic spinal cord compression by a rheumatoid nodule. Intern Med J 2004, 34:137-138.
76. Chen CL, Lee CH, Lee TS, et al.: Spinal epidural lipomatosis with thoracic osteoporotic compression fracture causing paraplegia. J Formos Med Assoc 2003, 102:429-434.
77. Mukai Y, Hosono N, Sakaura H, et al.: Laminoplasty for cervical myelopathy caused by subaxial lesion in rheumatoid arthritis. J Neurosurg Spine 2004, 100:7-12.
78. Vollertsen RS, Conn DL: Vasculitis associated with rheumatoid arthritis. Rheum Dis Clin North Am 1990, 16:445-461.
79. Ando Y, Kai S, Uyama E, et al.: Involvement of the central nervous system in rheumatoid arthritis: its clinical manifestations and analysis by magnetic resonance imaging. Intern Med 1995, 34:188-191.
80. Haigh RC, McCabe CS, Halligan PW, et al.: Joint stiffness in a phantom limb: evidence of central nervous system involvement in rheumatoid arthritis. Rheumatol 2003, 42:888-892.
81. Turesson C, Matteson EL: Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol 2004, 16:206-211.
82. Unger L, Kayser M, Nüsslein HG: Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 2003, 62:587-588. Three patients with rheumatoid vasculitis, manifested by cutaneous ulcers and systemic inflammation, responded well to infliximab infusion therapy.
83. Hietaharju A, Jaaskelainen S, Kalimo H, et al.: Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma). Muscle Nerve 1993, 16:1204-1212.
84. Hietaharju A, Jantti V, Korpela M, et al.: Nervous system involvement in systemic lupus erythematosus, Sjogren syndrome and scleroderma. Acta Neurol Scand 1993, 88:299-308.
85. Andonopoulos AP, Maraziotis T, Rigas G, et al.: Multiple spontaneous intracerebral hemorrhages in a patient with progressive systemic sclerosis. Rev Rhum Engl Ed 1988, 65:437-440.
86. Torabi AM, Patel RK, Wolfe GI, et al.: Transverse myelitis in systemic sclerosis. Arch Neurol 2004, 61:126-128.
87. Grosso S, Fioravanti A, Biasi G: Linear scleroderma associated with progressive brain atrophy. Brain Dev 2003, 25:57-61.
88. Hietarinta M, Lassila O, Hietaharju A: Association of anti-U1RNP- and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma). Scand J Rheumatol 1994, 23:64-67.
89. Héron E, Fornes P, Rance A, et al.: Brain involvement in scleroderma: two autopsy cases. Stroke 1998, 29:719-721.
90. Pathak R, Gabor AJ: Scleroderma and central nervous system vasculitis. Stroke 1991, 22:410-413.
91. Fox RI, Stern M, Michelson P: Update in Sjögren syndrome. Curr Opin Rheumatol 2000, 12:391-398.
92. Alexander E: Central nervous system disease in Sjögren's syndrome: new insights into immunopathogenesis. Rheum Dis Clin North Am 1992, 18:637-672.
93. Soliotis FC, Mavragani CP, Moutsopoulos HM: Central nervous system involvement in Sjögren's syndrome. Ann Rheum Dis 2004, 63:616-620.
94. Font J, Ramos-Casals M, de la Red G, et al.: Pure sensory neuropathy in primary Sjögren's syndrome: longterm prospective followup and review of the literature. J Rheumatol 2003, 30:1552-1557. In this comprehensive report, a purely sensory neuropathy was the most frequently seen PNS complication. A prolonged insidious course, sometimes with periods of stability, was typically observed.
95. Alexander EL, Ranzenbach MR, Kumar AJ, et al.: Anti-Ro(SS-A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology 1994, 44:899-908.
96. Valtysdottir ST, Gudbjornsson B, Lindqvist U, et al.: Anxiety and depression in patients with primary Sjögren's syndrome. J Rheumatol 2000, 27:165-169.
97. Belin C, Moroni C, Caillat-Vigneron N, et al.: Central nervous system involvement in Sjogren's syndrome: evidence from neuropsychological testing and HMPAO-SPECT. Ann Med Interne (Paris) 1999, 150:598-604.
98. Wang Y-J, Tsai K-Y, Fuh J-L, et al.: High frequency of primary Sjögren's syndrome in Taiwanese patients presenting as relapsing-remitting multiple sclerosis. Eur Neurol 2004, 51:21-25.
99. Pericot I, Brieva L, Tintore M, et al.: Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis. Mult Scler 2003, 9:256-259.
100. Mataró M, Escudero D, Ariza M, et al.: Magnetic resonance abnormalities associated with cognitive dysfunction in primary Sjögren syndrome. J Neurol 2003, 250:1070-1076. An increased incidence of affective disturbances and fatigue, associated with large ventricular volumes, was noted in patients with Sjögren syndrome versus control participants.
101. Kao CH, Lan JL, Changlai SP, et al.: Technetium-99m-HMPAO brain SPECT in Sjögren's syndrome. J Nucl Med 1998, 39:773-777.
102. Pierot L, Sauve C, Leger JM, et al.: Asymptomatic cerebral involvement in Sjögren's syndrome: MRI findings of 15 cases. Neuroradiology 1993, 35:378-380.
103. Alexander EL, Craft C, Dorsch C, et al.: Necrotizing arteritis and spinal subarachnoid hemorrhage in Sjogren syndrome. Ann Neurol 1982, 11:632-635.
104. Vincent TL, Richardson MP, Mackworth-Young CG, et al.: Sjögren's syndrome-associated myelopathy: response to immunosuppressive treatment. Am J Med 2003, 114:145-148.
105. van Bijsterveld OP, Kruize AA, Bleys RLAW: Central nervous system mechanisms in Sjögren's syndrome. Br J Ophthalmol 2003, 87:128-130. The discrepancies between clinical observations and disease severity are addressed by this interesting theory of the role of the CNS in Sjögren syndrome.
106. Rogers SJ, Williams CS, Roman GC: Myelopathy in Sjögren's syndrome: role of nonsteroidal immunosuppressants. Drugs 2004, 64:123-132. This is a comprehensive review of the nonsteroidal treatments of Sjögren syndrome.
107. Takahashi Y, Takata T, Hoshino M: Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. Neurology 2003, 60:503-505. The findings of a benefit in a chronic peripheral manifestation may have implications for the treatment of CNS manifestations.
108. Canhao H, Fonseca JE, Rosa A: Intravenous immunoglobulin in the treatment of central nervous system vasculitis associated with Sjögren's syndrome. J Rheumatol 2000, 27:1102-1103.
109. Caroyer JM, Manto MU, Steinfeld SD: Severe sensory neuronopathy responsive to infliximab in primary Sjögren's syndrome. Neurology 2002, 59:1113-1114.